PE2499A1 - Composiciones con recubrimientos que controlan la liberacion - Google Patents

Composiciones con recubrimientos que controlan la liberacion

Info

Publication number
PE2499A1
PE2499A1 PE1997000805A PE00080597A PE2499A1 PE 2499 A1 PE2499 A1 PE 2499A1 PE 1997000805 A PE1997000805 A PE 1997000805A PE 00080597 A PE00080597 A PE 00080597A PE 2499 A1 PE2499 A1 PE 2499A1
Authority
PE
Peru
Prior art keywords
active substance
dihydrogenocitrate
matrix
sodium
subject
Prior art date
Application number
PE1997000805A
Other languages
English (en)
Spanish (es)
Inventor
James Albert Napper
Susan Marie Milosovich
William Muldoon
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE2499A1 publication Critical patent/PE2499A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PE1997000805A 1996-09-12 1997-09-10 Composiciones con recubrimientos que controlan la liberacion PE2499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
PE2499A1 true PE2499A1 (es) 1999-03-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000805A PE2499A1 (es) 1996-09-12 1997-09-10 Composiciones con recubrimientos que controlan la liberacion

Country Status (22)

Country Link
EP (1) EP0929301A2 (de)
JP (1) JP2001500150A (de)
KR (1) KR20000036039A (de)
CN (2) CN1235544A (de)
AR (1) AR008176A1 (de)
AU (1) AU724086B2 (de)
BR (1) BR9711734A (de)
CA (1) CA2265661A1 (de)
CO (1) CO5031291A1 (de)
CZ (1) CZ83299A3 (de)
GB (1) GB9619074D0 (de)
HU (1) HUP9904401A3 (de)
ID (1) ID19589A (de)
IL (1) IL128781A0 (de)
MA (1) MA24359A1 (de)
NO (1) NO991194D0 (de)
NZ (1) NZ334268A (de)
PE (1) PE2499A1 (de)
PL (1) PL332074A1 (de)
TR (1) TR199900505T2 (de)
WO (1) WO1998010762A2 (de)
ZA (1) ZA978133B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
US6451343B1 (en) 1998-03-11 2002-09-17 Smithkline Beecham Corporation Composition for treating dementia and Alzheimer's disease
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
EP1617838A4 (de) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Zusammensetzung für die orale verabreichung mit alkylendioxybenzol-derivaten
PL1628642T3 (pl) * 2003-05-14 2007-01-31 Aptalis Pharma Ltd Kontrolowane uwalnianie lekarstwa z kompozycji odpornej in vivo na mechaniczny stres
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
WO2006015943A2 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1970056A1 (de) * 2007-03-15 2008-09-17 Polichem S.A. Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE269330T1 (de) * 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
KR20000036039A (ko) 2000-06-26
NO991194L (no) 1999-03-11
NO991194D0 (no) 1999-03-11
NZ334268A (en) 2000-10-27
AR008176A1 (es) 1999-12-09
GB9619074D0 (en) 1996-10-23
PL332074A1 (en) 1999-08-30
CN1235544A (zh) 1999-11-17
CN1446535A (zh) 2003-10-08
WO1998010762A2 (en) 1998-03-19
JP2001500150A (ja) 2001-01-09
CZ83299A3 (cs) 1999-08-11
HUP9904401A3 (en) 2001-03-28
CO5031291A1 (es) 2001-04-27
EP0929301A2 (de) 1999-07-21
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
MA24359A1 (fr) 1998-07-01
AU724086B2 (en) 2000-09-14
CA2265661A1 (en) 1998-03-19
BR9711734A (pt) 1999-08-24
ID19589A (id) 1998-07-23
TR199900505T2 (de) 1999-06-21
WO1998010762A3 (en) 1998-06-04
ZA978133B (en) 1999-04-12
AU4128897A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
PE2499A1 (es) Composiciones con recubrimientos que controlan la liberacion
US6106862A (en) Once daily analgesic tablet
EP0248447B1 (de) Formulierungen mit verzögerter Freisetzung
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
EP1021171B1 (de) Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
FI88675B (fi) Elastiska filmoeverdrag och deras anvaendning
Bernkop-Schnurch et al. Multifunctional matrices for oral peptide delivery
US5750145A (en) Stable gelatin coated aspirin tablets
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
BRPI0317682B1 (pt) Composição farmacêutica de liberação modificada na forma de uma cápsula
UA72483C2 (en) Moxifloxacin-containing pharmaceutical preparation and method for its manufacture
TW200602085A (en) Controlled-release pharmaceutical composition and method for producing same
HUP9900800A2 (hu) Szerves vegyületeket tartalmazó készítmények
BR9913696A (pt) Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial
ES2245071T3 (es) Procedimiento para obtener una preparacion de tramadol retardada con un perfil de liberacion estable en almacenamiento sin necesidad de tratar termicamente el producto revestido.
CA2229283A1 (en) Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease
US5958873A (en) Oral formulation for treatment of bacteria-induced diseases of the colon
IE58621B1 (en) Pancreatic enzyme products and a process for the preparation thereof
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
HUP0001084A2 (hu) 5-ASA-t tartalmazó, módosított hatóanyag-felszabadulást biztosító orális gyógyászati készítmény bélbetegségek kezelésére
Radolf et al. Penicillin-binding proteins and peptidoglycan of Treponema pallidum subsp. pallidum
ES2234301T3 (es) Acetaminofeno de liberacion prolongada.
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
RU97113855A (ru) Твердое инсулинсодержащее лекарственное средство

Legal Events

Date Code Title Description
FD Application declared void or lapsed